NASDAQ:CABA

Cabaletta Bio (CABA) Stock Forecast, Price & News

$15.22

+0.02 (+0.13%)

(As of 09/29/2023 ET)

Compare

Today's Range: $15.05
▼
$15.48
50-Day Range: $11.84
▼
$18.65
52-Week Range: $0.63
▼
$19.34

Volume: 596,887 shs
Average Volume: 1.05 million shs
Market Capitalization: $605.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Cabaletta Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 38.0% Upside
$21.00 Price Target
Short Interest: Bearish
7.89% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.29
Based on 3 Articles This Week
Insider Trading: Selling Shares
$492,910 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.51) to ($1.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

528th out of 972 stocks

Biological Products, Except Diagnostic Industry

77th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, Cabaletta Bio has a forecasted upside of 38.0% from its current price of $15.22.
Amount of Analyst Coverage
Cabaletta Bio has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.89% of the outstanding shares of Cabaletta Bio have been sold short.
Short Interest Ratio / Days to Cover
Cabaletta Bio has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Cabaletta Bio has recently decreased by 3.68%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cabaletta Bio does not currently pay a dividend.
Dividend Growth
Cabaletta Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CABA.

4.1

News and Social Media Coverage

News Sentiment
Cabaletta Bio has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cabaletta Bio this week, compared to 2 articles on an average week.
Search Interest
45 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
5 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cabaletta Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $492,910.00 in company stock.
Percentage Held by Insiders
12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cabaletta Bio are expected to grow in the coming year, from ($1.51) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cabaletta Bio is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cabaletta Bio is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cabaletta Bio has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cabaletta Bio (NASDAQ:CABA) Stock

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Price History

30 days | 90 days | 365 days | Advanced Chart

CABA Stock News Headlines

October 1, 2023 | americanbankingnews.com

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Rating of "Buy" from Analysts

September 25, 2023 | finance.yahoo.com

What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'

October 1, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

September 23, 2023 | markets.businessinsider.com

Promising Safety and Efficacy Data for Cabaletta Bio’s CD19 CAR-T Therapy Bolsters Buy Recommendation

September 19, 2023 | msn.com

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

September 8, 2023 | msn.com

Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable

September 5, 2023 | markets.businessinsider.com

Analyst Ratings for Cabaletta Bio

September 5, 2023 | cnbc.com

This little-known biotech stock has 'blockbuster potential,' says Citi

October 1, 2023 | Oxford Club (Ad)

Better Than Oil Stocks

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 5, 2023 | markets.businessinsider.com

Cabaletta Bio (CABA) Receives a Buy from Citi

August 31, 2023 | finance.yahoo.com

Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade

August 30, 2023 | finance.yahoo.com

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

August 25, 2023 | finance.yahoo.com

Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment

August 23, 2023 | finance.yahoo.com

Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why

August 22, 2023 | lse.co.uk

Oxford BioMedica expands licence deal with Cabaletta Bio

August 21, 2023 | finance.yahoo.com

We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth

August 15, 2023 | finance.yahoo.com

Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect?

August 14, 2023 | msn.com

Guggenheim Reiterates Cabaletta Bio (CABA) Buy Recommendation

August 12, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Cabaletta Bio (CABA)

August 12, 2023 | msn.com

HC Wainwright & Co. Maintains Cabaletta Bio (CABA) Buy Recommendation

August 12, 2023 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Cabaletta Bio: Here's What You Need To Know

August 10, 2023 | finance.yahoo.com

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023 | msn.com

Cabaletta Bio (CABA) Price Target Increased by 20.00% to 17.34

August 1, 2023 | msn.com

Top Growth Stocks for August 2023

July 24, 2023 | finance.yahoo.com

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

July 19, 2023 | msn.com

Guggenheim starts Cabaletta at buy, citing CAR-T therapy CABA-201

July 19, 2023 | nasdaq.com

Guggenheim Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation

See More Headlines

Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Company Calendar

Last Earnings: 8/10/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CABA
CUSIP: N/A
CIK: 1759138
Web: www.cabalettabio.com
Phone: 267-759-3100
Fax: N/A
Employees: 77
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.00
High Stock Price Forecast: $39.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +38.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.73)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,970,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -50.38%
Return on Assets: -46.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.93
Quick Ratio: 20.94

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.60 per share
Price / Book: 4.23

Miscellaneous

Outstanding Shares: 39,810,000
Free Float: 34,897,000
Market Cap: $605.91 million
Optionable: Not Optionable
Beta: 2.55

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Steven A. Nichtberger M.D. (Age 62)
Co-Founder, Chairman, CEO & Pres
Comp: $970.6k

Dr. Gwendolyn K. Binder Ph.D. (Age 48)
Pres of Science & Technology
Comp: $692.99k

Dr. David J. Chang FACR (Age 60)
M.D., M.P.H., Chief Medical Officer
Comp: $676.74k

Dr. Michael C. Milone M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board

Dr. Aimee Payne M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board

Mr. Anup Marda M.B.A. (Age 46)
Chief Financial Officer

Dr. Samik Basu M.D.
Chief Scientific Officer

Mr. Michael Gerard J.D. (Age 43)
Gen. Counsel & Sec.

Ms. Heather Harte-Hall M.Sc.
Chief Compliance Officer

Ms. Martha O'Connor
Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CABA Stock - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CABA shares.
View CABA analyst ratings or view top-rated stocks.
What is Cabaletta Bio's stock price forecast for 2023?: 7 Wall Street research analysts have issued twelve-month target prices for Cabaletta Bio's stock. Their CABA share price forecasts range from $10.00 to $39.00. On average, they predict the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 38.0% from the stock's current price.
View analysts price targets for CABA or view top-rated stocks among Wall Street analysts.
How have CABA shares performed in 2023?: Cabaletta Bio's stock was trading at $9.25 on January 1st, 2023. Since then, CABA stock has increased by 64.5% and is now trading at $15.22.
View the best growth stocks for 2023 here.
When is Cabaletta Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CABA earnings forecast.
How were Cabaletta Bio's earnings last quarter?: Cabaletta Bio, Inc. (NASDAQ:CABA) released its earnings results on Thursday, August, 10th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.10.
What ETFs hold Cabaletta Bio's stock?: ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Invesco DWA SmallCap Momentum ETF (DWAS).

What other stocks do shareholders of Cabaletta Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).
When did Cabaletta Bio IPO?: (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.
What is Cabaletta Bio's stock symbol?: Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."
How do I buy shares of Cabaletta Bio?: Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cabaletta Bio's stock price today?: One share of CABA stock can currently be purchased for approximately $15.22.
How much money does Cabaletta Bio make?: Cabaletta Bio (NASDAQ:CABA) has a market capitalization of $605.91 million. The company earns $-52,970,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.
How can I contact Cabaletta Bio?: Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The official website for the company is www.cabalettabio.com. The company can be reached via phone at 267-759-3100 or via email at investors@cabalettabio.com.

This page (NASDAQ:CABA) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial